NCT06092528 Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency
| NCT ID | NCT06092528 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gazi University |
| Condition | Primary Immunodeficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-09-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-11-01 with a primary completion date of 2025-09-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary immunodeficiencies (PID) are a heterogeneous group of diseases that occur as a result of disorders that affect the development, differentiation and/or function of various cells and building blocks in the immune system. Among the symptoms and complications of PID, pulmonary complications are very common and significantly increase the morbidity and mortality of the disease.
Eligibility Criteria
Inclusion Criteria: -Patients aged 6-18 years with primary immunodeficiency Exclusion Criteria: * Acute pulmonary exacerbation, acute upper or lower respiratory tract infection * Serious neurological, neuromuscular, orthopedic and other systemic diseases or other diseases affecting physical functions * Participating in a planned exercise program in the past three months * Cognitive impairment, which may cause difficulty understanding and following exercise test instructions
Contact & Investigator
Betül Yoleri, Pt. MsC
PRINCIPAL INVESTIGATOR
Gazi University
Frequently Asked Questions
Who can join the NCT06092528 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Primary Immunodeficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06092528 currently recruiting?
Yes, NCT06092528 is actively recruiting participants. Contact the research team at meralbosnak@gazi.edu.tr for enrollment information.
Where is the NCT06092528 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06092528 clinical trial?
NCT06092528 is sponsored by Gazi University. The principal investigator is Betül Yoleri, Pt. MsC at Gazi University. The trial plans to enroll 40 participants.